Myocardial infarction, stroke risk similar for metformin combo with insulin, sulfonylureas
the ONA take:
According to a study published online ahead of print in the journal Diabetes, Obesity and Metabolism, researchers have found that risk of heart attack or stroke is similar for treatment with sulfonylureas or insulin, plus metformin, among patients with type 2 diabetes.
For the study, researchers evaluated the risk of heart attack and stroke associated with sulfonylureas plus metformin and insulin plus metformin. Results showed that the risk of heart attack or stroke was similar in both groups.
"Current evidence suggests that there may not be large differences in cardiovascular risk associated with the use of insulin or sulfonylureas when used in combination with metformin," the authors concluded.
A study published last year in the Journal of the American Medical Association found that adding a sulfonylurea, rather than insulin, to metformin should be preferred in patients requiring a second antidiabetes medication. The study demonstrated that metformin plus insulin was decrease survival, but other experts questioned those results.
Risk of heart attack or stroke is similar for treatment with sulfonylureas or insulin, plus metformin, among patients with type 2 diabetes.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|